Cannabinoids provide a potential treatment option for disorders associated with traumatic memories, according to a new study.
The study was published in the journal European Neuropsychopharmacology, and e-published ahead of print by the U.S. National Institute of Health.
“Memory reconsolidation is the process in which reactivated long-term memory becomes transiently sensitive to amnesic agents”, states the study’s abstract. “We evaluated the ability of post reactivation administration of the mTOR inhibitor rapamycin, separately and in combination with the cannabinoid CB1/2 receptor agonist WIN55,212-2 (WIN) [meant to mimic the effects of natural cannabinoids]”. This was given “systemically or specifically into the hippocampal CA1 area, basolateral amygdala (BLA) or insular cortex (IC), to reduce inhibitory avoidance fear in rats.”